Review On Formulation And Evaluation Of In-Situ Gel Of Minoxidil

Abstract

The review focuses on the formulation and evaluation of in-situ gel of minoxidil Androgenic alopecia (AGA) significantly affects both physical appearance and psychological well-being, leading to progressive hair thinning due to genetic and hormonal factors. Minoxidil, an FDA-approved treatment, has long been a cornerstone for addressing AGA. Originally developed for hypertension, it was repurposed after its hair growth-promoting effects were discovered. Despite its effectiveness, conventional minoxidil formulations require frequent applications and can cause scalp irritation, limiting their overall eficacy and patient adherence. Main Body Hair growth cycles through anagen (growth), catagen (transition), and telogen (resting) phases. In AGA, the anagen phase shortens while the telogen phase lengthens, resulting in thinner hair. Minoxidil helps by extending the anagen phase and enlarging hair follicles. However, traditional formulations suffer from rapid solvent evaporation, leading to crystallization on the scalp and irritation. In-situ gels offer a novel solution, transforming from liquid to gel upon exposure to physiological conditions like temperature or pH changes. This allows for sustained release of minoxidil, maintaining effective drug concentrations on the scalp for longer periods and reducing the frequency of application. This approach enhances patient compliance and minimizes side effects. Conclusion In-situ gels represent a significant advancement in treating AGA by providing controlled, sustained drug release. They overcome the limitations of conventional minoxidil formulations, improving therapeutic outcomes and patient adherence. As research continues, in-situ gels hold the potential to revolutionize hair loss management.